Patoulias and colleagues have made a relevant commentary entitled “Chronic kidney
disease and diabetes status do not affect efficacy of SGLT-2 inhibitors in patients
with heart failure with reduced ejection fraction” [
[1]
] on our meta-analysis [
- Patoulias D
- Papadopoulos C
- Doumas M.
Chronic kidney disease and diabetes status do not affect efficacy of SGLT-2 inhibitors
in patients with heart failure with reduced ejection fraction.
EUR J INTERN MED. 2021; https://doi.org/10.1016/j.ejim.2021.02.009
[2]
] recently published in the European Journal of Internal Medicine (EJIM). In that commentary,
the authors, by implementing a further meta-analysis, assessed whether chronic kidney
disease (CKD) status and type 2 diabetes (T2D) status affected the efficacy of sodium-glucose
transporter 2 (SGLT2) inhibitors in patients with heart failure and reduced ejection
fraction (HFrEF). Although a previous meta-analysis [
- Qiu M
- Ding LL
- Zhan ZL
- Zhou HR.
Do four SGLT2 inhibitors lead to different cardiorenal benefits in type 2 diabetes,
in chronic heart failure, and in chronic kidney disease?.
EUR J INTERN MED. 2021; https://doi.org/10.1016/j.ejim.2021.01.009
[3]
] has already revealed that SGLT2 inhibitors significantly lower the risk of the heart
failure (HF) composite outcome of cardiovascular death (CVD) or hospitalization for
heart failure (HHF) in HFrEF patients regardless of CKD status and T2D status, meta-analysis
conducted in Patoulias et al.’s commentary [
[1]
] additionally reveals that SGLT2 inhibitors significantly lower the risk of CVD and
all-cause death (ACD) in HFrEF patients regardless of CKD status. However, Patoulias
et al.’s meta-analysis [
- Patoulias D
- Papadopoulos C
- Doumas M.
Chronic kidney disease and diabetes status do not affect efficacy of SGLT-2 inhibitors
in patients with heart failure with reduced ejection fraction.
EUR J INTERN MED. 2021; https://doi.org/10.1016/j.ejim.2021.02.009
[1]
] failed to completely clarify the issue of SGLT2 inhibitors for the treatment of patients
with two or three of the three kinds of diseases: T2D, CKD, and HF. Thus, we intended
to do an overall review of the efficacy of SGLT2 inhibitors in two or three concomitant
diseases based on the current compelling evidence, to extend the findings of our original
meta-analysis [
- Patoulias D
- Papadopoulos C
- Doumas M.
Chronic kidney disease and diabetes status do not affect efficacy of SGLT-2 inhibitors
in patients with heart failure with reduced ejection fraction.
EUR J INTERN MED. 2021; https://doi.org/10.1016/j.ejim.2021.02.009
[2]
] and Patoulias et al.’s meta-analysis [
- Qiu M
- Ding LL
- Zhan ZL
- Zhou HR.
Do four SGLT2 inhibitors lead to different cardiorenal benefits in type 2 diabetes,
in chronic heart failure, and in chronic kidney disease?.
EUR J INTERN MED. 2021; https://doi.org/10.1016/j.ejim.2021.01.009
[1]
].- Patoulias D
- Papadopoulos C
- Doumas M.
Chronic kidney disease and diabetes status do not affect efficacy of SGLT-2 inhibitors
in patients with heart failure with reduced ejection fraction.
EUR J INTERN MED. 2021; https://doi.org/10.1016/j.ejim.2021.02.009
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Chronic kidney disease and diabetes status do not affect efficacy of SGLT-2 inhibitors in patients with heart failure with reduced ejection fraction.EUR J INTERN MED. 2021; https://doi.org/10.1016/j.ejim.2021.02.009
- Do four SGLT2 inhibitors lead to different cardiorenal benefits in type 2 diabetes, in chronic heart failure, and in chronic kidney disease?.EUR J INTERN MED. 2021; https://doi.org/10.1016/j.ejim.2021.01.009
- SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.LANCET. 2020; 396: 819-829
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.LANCET. 2019; 393: 31-39
- Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.J AM HEART ASSOC. 2020; 9: e14908
- Do reductions in risk of cardiorenal events with SGLT2 inhibitors in type 2 diabetes vary with baseline characteristics? A meta-analysis.ENDOCRINE. 2020; 69: 688-691
- Dapagliflozin in Patients with Chronic Kidney Disease.N Engl J Med. 2020; 383: 1436-1446
- Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.N Engl J Med. 2021; 384: 117-128
- Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.N Engl J Med. 2021; 384: 129-139
Article info
Publication history
Published online: March 12, 2021
Accepted:
March 1,
2021
Received in revised form:
February 26,
2021
Received:
February 15,
2021
Identification
Copyright
© 2021 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.